Posaconazole is effective as salvage therapy in zygomycosis: a retrospective summary of 91 cases

Clin Infect Dis. 2006 Apr 1;42(7):e61-5. doi: 10.1086/500212. Epub 2006 Feb 21.


To evaluate the activity of posaconazole for treatment of zygomycosis, a disease for which therapeutic options are limited, we conducted a retrospective study including 91 patients with zygomycosis (proven zygomycosis, 69 patients; probable zygomycosis, 22 patients). Patients had infection that was refractory to prior antifungal treatment (n=81) or were intolerant of such treatment (n=10) and participated in the compassionate-use posaconazole (800 mg/day) program. The rate of success (i.e., either complete or partial response) at 12 weeks after treatment initiation was 60%, and 21% of patients had stable disease. The overall high success and survival rates reported here provide encouraging data regarding posaconazole as an alternative therapy for zygomycosis.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Aged, 80 and over
  • Antifungal Agents / therapeutic use*
  • Child
  • Female
  • Humans
  • Male
  • Middle Aged
  • Retrospective Studies
  • Salvage Therapy
  • Triazoles / therapeutic use*
  • Zygomycosis / drug therapy*


  • Antifungal Agents
  • Triazoles
  • posaconazole